MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.56 USD
+0.11 (3.19%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $3.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.56 USD
+0.11 (3.19%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $3.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -89.36% and 55.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 6.90% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -188.46% and 58.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 18.24% and 1.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why
by Zacks Equity Research
MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.
MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Soars 19.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -157.01% and 81.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 170% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
by Zacks Equity Research
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?
by Zacks Equity Research
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MacroGenics (MGNX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
MacroGenics (MGNX) closed the most recent trading day at $5.70, moving -0.35% from the previous trading session.
Zacks.com featured highlights MacroGenics, NerdWallet and Euronav
by Zacks Equity Research
MacroGenics, NerdWallet and Euronav have been highlighted in this Screen of The Week article.
Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 73.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Buy These 3 Top Stocks for Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & Euronav (EURN) at the moment for superb earnings acceleration.
MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Here's How to Find Cheap Stocks Under $10 to Buy for December
by Benjamin Rains
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...